We are creating novel small molecules and antisense oligonucleotides for a variety of serious genetic conditions. With a current focus in neurological disorders, our technology platform can also be leveraged to discover therapeutic candidates across many disease areas.
Spastic Paraplegia Type 49
GBA Parkinson's Disease
Silverstein Foundation for Parkinson's with GBA
Undisclosed Genetic Disorder